Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.56 |
| ▸ | DRD3 | P35462 | 11/20 | 0.56 |
| ▸ | HTR2A | P28223 | 4/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL224684 | 1.00 | DRD2 (0.56) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227340 | 0.97 | DRD2 (0.60) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227341 | 0.97 | DRD2 (0.60) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227209 | 0.96 | HTR2A (0.57) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227208 | 0.96 | HTR2A (0.57) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227207 | 0.92 | HTR2A (0.53) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227206 | 0.92 | HTR2A (0.53) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL227205 | 0.92 | HTR2A (0.53) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL228670 | 0.91 | HTR2A (0.62) | DRD2DRD3HTR2AHTR2CHTR7 | |
| SCHEMBL228709 | 0.91 | HTR2A (0.52) | DRD2DRD3HTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8415350-B2 | Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors | HOFFMANN-LA ROCHE INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | GOBBI LUCA (CH) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004208-A1 | BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS | HTR2A, HTR3A, HTR2C | DRD2 16/4885DRD3 18/4885HTR2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.